Suggested remit - To appraise the clinical and cost effectiveness of ixekizumab within it marketing authorisation for treating axial spondyloarthritis
 
Status In progress
Process STA 2018
ID number 1532

Provisional Schedule

Committee meeting: 1 14 July 2020
Expected publication 23 September 2020

Project Team

Project lead Thomas Feist

Email enquiries

Consultees

Companies sponsors Eli Lilly
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups National Axial Spondyloarthritis Society
Professional groups British Society for Rheumatology
  Royal College of Physicians

Commentators

Comparator companies Abbvie
  Amgen
  Biogen
  Novartis
  Pfizer
  UCB Pharma
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department for Health, Social Services and Public Safety - Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
08 November 2019 Invitation to participate
08 November 2019 In progress
31 January 2019 - 28 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance